Aditxt logo

Aditxt(NASDAQ) ADTX

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-100%
5 YearN/A
1 Year-100%
1 Month-59%
N/A
Aditxt last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-13
Aditxt stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.5%USD 0.002026-10-06
1 month-58.82%USD 0.012026-09-11
3 month-12.77%USD 0.002026-07-15
Year to date-100%USD 180.252025-12-31
1 year-100%USD 12,321.162025-10-13
Since inception-100%USD 93.692026-03-09

Aditxt Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$14.34K

Net Income (TTM)

-$51.95M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 2, 2026

ADTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aditxt

Aditxt, Inc. is a biotechnology firm focused on enhancing immune system health through innovative mapping and reprogramming techniques. The company offers unique solutions aimed at empowering individuals with insights into their immune profiles, thereby improving management of immune-related conditions.

Products and Services
  • AditxtScore platform for immune profile insights
  • Apoptotic DNA Immunotherapy for self-tolerance
  • ADi products targeting organ transplants and autoimmune conditions
Growth Outlook
  • Established partnerships with Loma Linda University and Stanford University
  • Continued research into diverse therapeutic applications
  • Focus on expanding product offerings in immune health
Financial Highlights
  • Recent quarterly revenue of 12,159, showing potential growth
  • Trailing twelve months (TTM) revenue of 1,425, indicating a developing market presence
  • Cash and cash equivalents of 268,852, providing operational liquidity
Aditxt, Inc. is positioned in the biotechnology sector, with a mission to advance immune health through innovative solutions. The company's flagship product, AditxtScore, provides individuals with valuable insights into their immune profiles, which can lead to better health management. Additionally, the Apoptotic DNA Immunotherapy represents a significant advancement in the field, aiming to help the body develop self-tolerance to its own tissues. The growth outlook for Aditxt is promising, bolstered by strategic partnerships with reputable institutions and ongoing research into various therapeutic applications. This focus on innovation and collaboration may enhance the company's market position and product offerings in the future. Financially, Aditxt has shown signs of growth, with a recent quarterly revenue of 12,159 and a TTM revenue of 1,425. The company maintains a cash position of 268,852, which supports its operational needs. As Aditxt continues to develop its products and expand its market reach, it may attract interest from investors looking for opportunities in the biotechnology sector.
AI Generated • Sep 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

26

CEO

Amro Albanna

Website

www.aditxt.com

Headquarters

Mountain View, CA 94043, US

ADTX Financials

Key Financial Metrics (TTM)

Gross Margin

19.89%

Operating Margin

-127821.37%

Net Income Margin

-362385.72%

Return on Equity

926.02%

Return on Capital

-227.14%

Return on Assets

-373.57%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$2.85K

Operating Income

-$18.32M

EBITDA

-$50.69M

Operating Cash Flow

-$18.55M

Capital Expenditure

-$10.38K

Free Cash Flow

-$18.58M

Cash & ST Invst.

$268.85K

Total Debt

$4.23M

Aditxt Performance Analysis

Aditxt annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 933,715789.0%
20232023-12-31USD 645,176-30.9%
20242024-12-31USD 133,985-79.2%
20252025-12-31USD 3,195-97.6%
Aditxt sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1.4%
Q32025-09-30-25.5%
Q42025-12-31-43.2%
Q12026-03-312760.9%
Aditxt annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -145,349,640,402.79122851376331.4%
20232023-12-31USD -26,397,986,689.52-81.8%
20242024-12-31USD -74,747,547.75-99.7%
20252025-12-31USD -31,153.51-100.0%
Aditxt sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3057.5%
Q32025-09-30-15806.7%
Q42025-12-3173.0%
Q12026-03-31-434.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$12.16K

+1094.4%

Gross Profit

$2.87K

+909.9%

Gross Margin

23.59%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

26

N/A

Net Income

-$15.95M

-179.3%

EBITDA

-$16.09M

-191.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$268.85K

-43.6%

Total Debt

$4.23M

+4.0%

Accounts Receivable

$11.97K

-98.2%

Inventory

$128.37K

+1317.3%

Long Term Debt

$288.89K

+4.2%

Short Term Debt

$3.94M

+3.9%

Return on Assets

-3.74%

N/A

Return on Invested Capital

-32.42%

N/A

Free Cash Flow

-$4.59M

+60.8%

Operating Cash Flow

-$4.58M

+60.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AIMDAinos, Inc.
$1.08-5.26%
ICUSeaStar Medical Holding Corporation
$3.59-6.75%
GOVXGeoVax Labs, Inc.
$0.27-5.92%
APLMApollomics, Inc.
$21.52+0.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About ADTX

What is the current price of Aditxt?

Aditxt is trading at N/A per share.

What is the 52-week range for Aditxt?

Over the past 52 weeks, Aditxt has traded between N/A and N/A.

How much debt does Aditxt have?

As of the most recent reporting period, Aditxt reported total debt of $5.67M.

How much cash does Aditxt have on hand?

Aditxt reported $268.85K in cash and cash equivalents in its most recent financial results.

What is Aditxt’s dividend yield?

Aditxt does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services